Andra AP fonden lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 369,050 shares of the company’s stock after acquiring an additional 16,450 shares during the period. Johnson & Johnson makes up approximately 1.1% of Andra AP fonden’s portfolio, making the stock its 2nd largest position. Andra AP fonden’s holdings in Johnson & Johnson were worth $47,980,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in JNJ. Harding Loevner LP purchased a new stake in Johnson & Johnson in the second quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. IHT Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after acquiring an additional 3,467 shares during the last quarter. Mountain Capital Investment Advisors Inc purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth $124,000. Finally, Shine Investment Advisory Services Inc. purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth $177,000. 65.71% of the stock is owned by institutional investors.
Johnson & Johnson (JNJ) opened at $147.36 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a one year low of $110.76 and a one year high of $148.32. The firm has a market cap of $395,890.00, a price-to-earnings ratio of 25.58, a P/E/G ratio of 2.76 and a beta of 0.80.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.28%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 58.33%.
Several research analysts have recently weighed in on JNJ shares. Cowen reiterated an “outperform” rating and set a $155.00 price target (up previously from $147.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Jefferies Group lifted their price target on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Finally, Barclays lifted their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $145.94.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.truebluetribune.com/2018/01/22/andra-ap-fonden-increases-position-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.